Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, and Hepatocellular Carcinoma Treatment and Prognosis.
Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China
A large-scale study integrating CEA and tumor deposits to evaluate prognosis in colon cancer patients
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial
Novel methyltransferase G9a inhibitor induces ferroptosis in multiple myeloma through Nrf2/HO-1 pathway
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice
Novel Methyltransferase G9a Inhibitor Induces Ferroptosis in Multiple Myeloma Through Nrf2/HO-1 Pathway
Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance
Baseline and early changes in the neutrophil–lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy
Shenlingcao oral liquid for patients with non-small cell lung cancer receiving adjuvant chemotherapy after radical resection: A multicenter randomized controlled trial
A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges
Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study
Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients
Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.
Improvement of Asia-Pacific colorectal screening score and evaluation of its use combined with fecal immunochemical test
The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases
Fibrinogen promotes malignant biological tumor behavior involving epithelial–mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma
Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression
Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development